Click Here for 5% Off Your First Aladdin Purchase!

GW274150 phosphate - 10mM in Water, high purity , CAS No.438542-15-5(Water)

  • 10mM in Water
Item Number
G654489
Grouped product items
SKUSizeAvailabilityPrice Qty
G654489-1ml
1ml
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$82.90

Basic Description

Specifications & Purity10mM in Water
Storage TempArgon charged,Store at -80°C
Shipped InIce chest + Ice pads
Product Description

GW274150 phosphate is a potent, selective, orally active and NADPH-dependent inhibitor of human inducible nitric oxide synthase (iNOS) ( IC 50 =2.19 μM; K d =40 nM) and rat iNOS ( ED 50 =1.15 μM). GW274150 phosphate displays less potency for both humans or rats endothelial NOS ( eNOS ) and neuronal NOS ( nNOS ). GW274150 phosphate exerts a protective role in an acute model of lung injury inflammation

In Vitro

GW274150 phosphate inhibits intracellular iNOS in J774 cells in a time-dependent manner, reaching IC 50 values of 0.2±0.04 μM. GW274150 is >260-fold and 219-fold selective for iNOS against eNOS and nNOS in rat tissues, respectively. And it displays >100-fold and >80-fold for human iNOS against human eNOS and nNOS, respectively. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

GW274150 phosphate is a long-acting (5 h half‐life in rats) iNOS inhibitor and is able to inhibit LPS‐mediated increase in plasma NO2 - , NO3 - levels 14 h after single intraperitoneal dose (ED 50 =3 mg/kg). GW274150 phosphate (intraperitoneal injection; 2.5, 5, and 10 mg/kg; before carrageenan injection) reduces the degree of lung injury induced by carrageenan in a dose-related fashion. Oedema formation and PMNs infiltration in the pleural cavity are also significantly attenuated in a dose‐related manner in rats. GW274150 phosphate (oral adminstration; 30 mg/kg; twice daily; 7 days) leads to significant neuroprotection, however, it displays a bell-shaped neuroprotective profile, being ineffective at high doses in 6-OHDA rat model of Parkinson disease (PD). MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: SD ratDosage: 2.5, 5 and 10 mg/kg Administration: Intraperitoneal injection 5 min before carrageenan injection Result: Exerted a protective role in an acute model of inflammation, carrageenan-induced lung injury.

IC50& Target:Kd: 40 nM (iNOS), IC50: 2.19 μM (human iNOS),544 μM (human eNOS),177 μM (human nNOS) ED50: 1.15 μM (rat iNOS),252 μM (rat nNOS)

Names and Identifiers

Canonical SMILES CC(NCCSCC[C@H](N)C(O)=O)=N.O=P(O)(O)O
Molecular Weight 317.30

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Related Documents

Solution Calculators